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Abstract
Background: Therapeutically bioactive cell populations are currently understood to promote regenerative
outcomes in vivo by leveraging mechanisms of action including secretion of growth factors, site specific
engraftment and directed differentiation. Constitutive cellular populations undoubtedly participate in the
regenerative process. Adipose tissue represents a source of therapeutically bioactive cell populations. The potential
of these cells to participate in various aspects of the regenerative process has been demonstrated broadly.
However, organ association of secretory and developmental markers to specific peri-organ adipose depots has not
been investigated. To characterize this topographical association, we explored the potential of cells isolated from
the stromal vascular fraction (SVF) of kidney sourced adipose to express key renal associated factors.
Results: We report that renal adipose tissue is a novel reservoir for EPO expressing cells. Kidney sourced adipose
stromal cells demonstrate hypoxia regulated expression of EPO and VEGF transcripts. Using iso-electric focusing, we
demonstrate that kidney and non-kidney sourced adipose stromal cells present unique patterns of EPO post-
translational modification, consistent with the idea that renal and non-renal sources are functionally distinct
adipose depots. In addition, kidney sourced adipose stromal cells specifically express the key renal developmental
transcription factor WT1.
Conclusions: Taken together, these data are consistent with the notion that kidney sourced adipose stromal
(KiSAS) cells may be primed to recreate a regenerative micro-environment within the kidney. These findings open
the possibility of isolating solid-organ associated adipose derived cell populations for therapeutic applications in
organ-specific regenerative medicine products.
Keywords: erythropoietin, EPO, adipose, kidney, chronic kidney disease, VEGF, WT1, regenerative medicine, tissue
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Background
Adipose is recognized as an endocrine organ with signif-
icant metabolic bioactivity. Adipose tissue is composed
of adipocytes, vascular endothelial cells, pericytes, fibro-
blasts, macrophages, stem cells and progenitors with
MSC-like bioactivity and smooth muscle-like cells [1-4].
Of these, MSC-like and smooth muscle-like cell popula-
tions are currently under active development for appli-
cation in tissue engineering and regenerative medicine
[5]. At a higher level, adipose tissue may be classified as
white or brown based on the preponderance of white or
brown adipocytes. White adipocytes represent the prin-
cipal lipid storage vehicle within adipose tissue, whereas
brown adipocytes are responsible for mediating lipid
metabolism and are therefore correspondingly enriched
in mitochondria. Adipose tissue may be found distribu-
ted broadly throughout the body as distinctive, region
specific depots. The principal depots for white adipose
tissue (WAT) are abdominal subcutaneous and visceral
adipose tissue (SAT and VAT). VAT may itself be
further subdivided into omental, mesenteric, retroperito-
neal, gonadal and pericardial depots [6,7]. Adipose
depots are characterized by unique patterns of structural
organization, transcriptomic, proteomic and secretomic
expression profiles and biological function. For example,
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secretomes generated by visceral, subcutaneous and
gonadal adipose depots are specific to source [8].
Furthermore, significant functional differences between
subcutaneous, epididymal and mesenteric adiposes have
been observed through transcriptomic and lipidomic ana-
lysis of transgenic mice with humanized lipoprotein pro-
files [9]. Finally, the multi-lineage differentiation
potential of adipose-derived stromal cells with MSC-like
bioactivity has been shown to be dependant on the depot
of origin [10,11]. These systemic observations notwith-
standing, analysis and characterization of transcriptomic,
proteomic and functional differences between adiposes
associated with individual organs remains to be investi-
gated. More specifically, understanding the variation in
regenerative potentials presented by stromal cells derived
from differently sourced solid organ associated adiposes
may significantly impact the development of tissue engi-
neering and regenerative medicine (TE/RM) products
targeted to those organs. As a follow-up to our recently
reported neo-kidney augment work [12], we have focused
in the current study on evaluation of key functional cri-
teria discriminating stromal cells derived from kidney
and non-kidney sourced adiposes through analysis of
established regenerative and developmental markers
associated with kidney: erythropoietin (EPO), VEGF and
WT1. We demonstrate for the first time that renal adi-
pose tissue presents depot specific expression of EPO,
and that stromal cell populations derived from kidney
and non-kidney sourced adiposes express EPO and
VEGF in a hypoxia-regulated manner. Furthermore, we
show that expression of the key nephrogenic transcrip-
tion factor WT1 is specific to kidney adipose sourced
stromal cells, and that niche specific adipose depots
within kidney may be defined by distinctive WT1 tran-
scriptional splice variants. Taken together, these data
extend the concept of functionally unique, location-speci-
fic adipose depots from the systemic to the organ-level,
and establish a foundation for application of kidney
sourced adipose as an alternate cell source for tissue
engineering and regenerative therapies of the kidney.
Results
EPO is expressed by multiple cell sources
To evaluate expression of EPO mRNA from adipose-
derived stromal cells relative to established sources of
EPO, TaqMan quantitative RT-PCR was performed [13].
As shown in Figure 1, strong expression of EPO is
observable from renal primary cells (cell type 2), fetal
liver (cell type 3), adult hepatocytes (cell type 5), kerati-
nocytes (cell types 6 and 8) and non-mobilized CD34+
PBMNC (cell type 10). Mobilization of CD34+ PBMNC
with GCSF was observed to lead to silencing of EPO
mRNA expression (cell type 9). Relatively lower levels of
EPO mRNA were observed from multiple samples of
non-kidney sourced adipose stromal cells such as CD34
+ enriched fetal liver cells (cell type 4) as well as pas-
saged lipoaspirate (cell types 11-14) and subcutaneous
(cell types 15-10) adipose stromal cells. EPO expression
was also evaluated from kidney and non-kidney sourced
adipose stromal cells directly against renal primary cells.
As shown in Figure 2, expression of EPO mRNA from
both kidney and non-kidney sourced adipose stromal
cells (cell types 4-7, 9, 10) is comparable to that
observed from primary kidney cells (cell types 1-3).
Expression of EPO mRNA from kidney and non-kidney
sourced adipose stromal cells is regulated by hypoxia
A key characteristic of EPO expression from kidney is reg-
ulation by environmental oxygen [14,15]. Based on this
criterion, an experiment was performed to establish
whether expression of EPO from adipose stromal cells was
physiologically relevant by quantifying the production of
EPO mRNA under conditions of high and low environ-
mental oxygen. Initial studies focused on rodents, as the
rat is the small animal model of choice for the investiga-
tion of CKD [16]. As shown in Figure 3, rat visceral adi-
pose stromal cells respond to hypoxia by an up-regulation
of the expression of EPO mRNA within 4 hours of treat-
ment. Expression of VEGF mRNA from rat visceral adi-
pose stromal cells is also tightly controlled by hypoxia,
showing up-regulation within 4 hours of treatment and
Figure 1 EPO is expressed by multiple cell types as
determined by TaqMan qRTPCR comparative analysis of the
indicated human cell and tissue sources. Human primary renal
cells were used as calibrator and have a designated RQ value of 1.0.
Samples are as follows: H2O as a negative control (1); human
primary renal cells (2); whole fetal liver (3); CD34+ enriched fetal
liver cells (4); hepatocytes (5); keratinocytes at passage 4 (6); human
dermal microvascular endothelial cells (7); human epidermal
keratinocytes (8); peripheral blood derived mononuclear cells, CD34
+, GCSF mobilized (9); peripheral blood derived mononuclear cells,
CD34+, normal (10); adipose (lipoaspirate) stromal cells at passage 0
(11); passage 1 (12); passage 2 (13); passage 4 (14); adipose
(subcutaneous) stromal cells at passage 0 (15); passage 1 (16);
passage 2 (17); passage 3 (18); and passage 4 (19).
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subsequent down-regulation within 48 hours of return to
normoxia (Figure 4). This result is reflected by human
KiSAS cells. As shown in Figures 5, 6, 7, 8, hypoxia
induced up-regulation of EPO and VEGF mRNA expres-
sion was observed from human renal pedicle and major
calyx sourced adipose stromal cells.
Expression of EPO protein is comparable between human
KiSAS cells and human renal primary cells
Although expression levels of EPO mRNA in adipose
stromal cells are significantly lower relative to primary
renal cells, quantitation of EPO mRNA is secondary
from a functional or bio-therapeutic perspective to eva-
luation of EPO protein expression between differently
sourced adiposes. We therefore investigated expression
of EPO protein from adipose sourced stromal cells
using iso-electric focusing gels (IEF). IEF technology has
been used to discriminate between multiple, differently
modified isoforms of EPO with high resolution [17]. Fig-
ure 9 demonstrates that EPO protein is expressed from
human KiSAS cells (lane 3) at levels directly comparable
to that observed from established cell sources of EPO,
including keratinocytes (lane 1), hepatocytes (lane 2),
and primary kidney cells (lanes 5, 6) [18,19]. EPO is also
expressed by visceral (non-renal) adipose stromal cells
(lane 4), but at significantly reduced levels. Kidney and
non-kidney sourced adipose stromal cells show
Figure 2 Expression of EPO from kidney and non-kidney
sourced adipose stromal cells is comparable to primary renal
cells as determined by TaqMan qRT-PCR comparative analysis.
Samples are as follows: Primary renal cells (1 and 2); primary renal
cells exposed to hypoxic conditions (3); adipose lipoaspirate (4) and
subcutaneous (5) stromal cells at passage 0; adipose lipoaspirate (6)
and subcutaneous (7) stromal cells at passage 1; major calyx derived
kidney sourced adipose stromal cells at passage 1 (8); renal pedicle
derived kidney sourced adipose stromal cells at passage 1 (9) and
passage 3 (10); fetal hepatocytes used as a positive control (11); H2O
used as a negative control (12).
Figure 3 Regulated expression of EPO from rat visceral
adipose stromal cells as determined by TaqMan qRT-PCR
analysis. EPO expression is up-regulated in response to hypoxia
within 4 hours, and returns towards baseline within 48 hours of
transfer to normoxia (n = 3).
Figure 4 Regulated expression of VEGF from rat visceral
adipose stromal cells as determined by TaqMan qRT-PCR
analysis. VEGF expression is up-regulated in response to hypoxia
within 4 hours, and returns towards baseline within 48 hours of
transfer to normoxia (n = 3).
Figure 5 Regulated expression of EPO from human renal
pedicle adipose stromal cells as determined by TaqMan qRT-
PCR analysis. EPO expression is up-regulated in response to
hypoxia within 4 hours, and returns towards baseline for renal
pedicle sourced adipose (n = 3).
Basu et al. Lipids in Health and Disease 2011, 10:171
http://www.lipidworld.com/content/10/1/171
Page 3 of 10
distinctive patterns of post-translational EPO modifica-
tion resulting in unique migration profiles on IEF gels,
as can be seen by comparing lane 3 with lane 4. In addi-
tion, EPO from kidney or non-kidney sourced adipose
stromal cell sources is further distinguishable from EPO
expressed by primary renal cells on the basis of iso-elec-
tric point (compare lanes 3 and 4 with lanes 5 and 6).
Finally, EPO isoforms expressed by human keratinocytes
and hepatocytes (lanes 1 and 2) are distinguishable from
all other cell sources.
As dog is the large animal model of choice for evalua-
tion of renal cell therapies [20], we examined expression
of EPO protein in canine kidney sourced adipose stromal
cells and primary renal cells using IEF gels. Figure 10
demonstrates that canine KiSAS cells sourced from either
major calyx adipose (lane 3) or renal pedicle adipose (lane
4) express EPO protein at levels comparable to that
observed from canine primary renal cells (lanes 1 and 2).
Additionally, as is the case for human adipose, EPO
expressed from stromal cells sourced from either the renal
Figure 6 Regulated expression of EPO from human major calyx
adipose stromal cells as determined by TaqMan qRT-PCR
analysis. EPO expression is up-regulated in response to hypoxia
within 4 hours, and returns towards baseline within 48 hours of
transfer to normoxia (n = 3) for major calyx sourced adipose.
Figure 7 Regulated expression of VEGF from human renal
pedicle adipose stromal cells as determined by TaqMan qRT-
PCR analysis. VEGF expression is up-regulated in response to
hypoxia within 4 hours, and returns towards baseline within 48
hours of transfer to normoxia (n = 3).
Figure 8 Regulated expression of VEGF from human major
calyx adipose stromal cells as determined by TaqMan qRT-PCR
analysis. VEGF expression is up-regulated in response to hypoxia
within 4 hours, and returns towards baseline within 48 hours of
transfer to normoxia (n = 3).
Figure 9 Expression of EPO from human kidney and non-
kidney sourced adipose stromal cells is comparable with
primary renal cells, hepatocytes and keratinocytes. Kidney and
non-kidney sourced adipose stromal cells express distinct isoforms
of EPO distinguishable though isoelectric focusing gel
electrophoresis and western blotting. Samples are as follows: human
keratinocytes (1), hepatocytes (2), renal- (3) non-renal- (4) adipose
stromal- cells and primary renal-cells all under normoxia (5), primary
renal cells under hypoxia (6) and HepG2 cells as a positive control
(7). Blot was probed with anti-EPO monoclonal antibody for
Western analysis. Comparison of lanes 5 and 6 shows clear up-
regulation of EPO protein expression in response to hypoxia from
primary renal cell isolates. All lanes were normalized by total mass
of protein (10 μg).
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pedicle or major calyx have unique IEF signatures that dis-
criminate canine adipose sourced EPO from that
expressed by canine primary renal cells. Taken together,
these data establish that KiSAS cells express EPO protein
at levels comparable to that seen from established cellular
sources of EPO including renal cells, hepatocytes and ker-
atinocytes and confirm that differently sourced EPO may
be identified by iso-electric point profiling [17-19].
Kidney sourced adipose tissue is an organ-specific
reservoir for EPO
To establish if expression of EPO from adipose stromal
cell populations reflects a physiologically relevant EPO
reservoir in vivo, or is simply an artifact associated with
cell culturing, we examined expression of EPO protein
from differently sourced rat whole adipose tissue by IEF.
As shown in Figure 11 where individual lanes are normal-
ized by mass protein loaded, robust expression of EPO is
specifically associated with kidney sourced adipose tissue.
Although EPO is detectable from non-kidney organ
sources of adipose tissue such as liver and heart, expres-
sion is 5-fold higher in kidney sourced adipose over liver
sourced adipose and 2.8-fold higher in kidney sourced adi-
pose over heart sourced adipose. Interestingly, comparison
of white and brown adiposes sourced from visceral adipose
depots shows EPO expression is 5-fold higher in white
adipose over brown adipose.
Expression of the developmental transcription factor WT1
distinguishes kidney from non-kidney sourced adipose
stromal cells
We reasoned that renal markers other than EPO might
be associated with organ specific expression patterns
within differently sourced adiposes. WT1 is a key zinc
finger transcription factor broadly involved in organo-
genesis. WT1 acts to modulate the earliest stages of
nephrogenesis, and may serve as a marker for regenera-
tion [21-23]. We used primers specific to the KTS+ and
KTS- transcriptional splice variants of WT1 [24] to
investigate the expression of WT1 within kidney and
non-kidney sourced adipose stromal cells. As shown in
Figure 12, expression of WT1 mRNA is specific to kid-
ney sourced adipose stromal cells (lanes MC and RP),
with no expression being observed from visceral adipose
stromal cells (lanes LA and SQ). Interestingly, the ratio
of these two splice variants differs between stromal cells
sourced from major calyx adipose (lane MC) or renal
pedicle adipose (lane RP) derived from the same donor.
We extended the WT1 RT-PCR analysis by evaluating
expression of WT1 protein in KiSAS cells through FACs
and immuno-fluorescence approaches. Figures 13, 14
show that both renal pedicle and major calyx sourced
adipose stromal cells have a WT1+ population, ranging
from approximately 45% (renal pedicle) to 52% (major
calyx) of the population. Expression of WT1 is both
nuclear and cytoplasmic, (Figure 15), as has been pre-
viously reported [25].
Discussion
Cell therapy strategies for the treatment of CKD have
typically focused on application of mesenchymal stem
cells (MSC) (renal or bone-marrow derived) or embryo-
nic and fetal progenitors. Evidence for therapeutic effi-
cacy remains mixed, with little or no demonstration of
localized engraftment and differentiation towards an
endogenous renal cell population [26,27]. Current
Figure 10 Expression of EPO from canine KiSAS cells is
comparable to canine primary renal cells. Samples are as follows:
canine primary renal cells under normoxia (1) and hypoxia (2), major
calyx-derived adipose stromal cells (3), renal pedicle derived-adipose
stromal cells (4) and recombinant canine EPO as a positive control
(5). Blot was probed with anti-EPO monoclonal antibody for Western
analysis. All lanes were normalized by total mass of protein (10 μg)
Figure 11 Adipose tissue is a reservoir for EPO expressing cells
distinguishable though isoelectric focusing gel electrophoresis
and western blotting. White and brown adipose are derived from
visceral depot. All lanes normalized by mass of protein to 10 μg.
Table shows quantitative densitometric analysis of EPO expression
expressed as band intensity per unit gel area.
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thinking regarding the therapeutic mechanism of action
of MSC and other related progenitor populations has
emphasized their trophic function as cellular vectors for
secreting large quantities of cytokines and growth fac-
tors into the extracellular milieu, thereby facilitating the
re-creation of a regenerative micro-environment [28].
To this end, cells with MSC-like bioactivity may be
sourced from multiple organ systems including adipose
[1,2]. However, differently sourced MSC-like cells may
not be functionally equivalent. For example, numerous
functional and phenotypic differences have been docu-
mented between MSC sourced from either adipose or
bone marrow [5,12]. MSC bioactivity within a given
organ source may also be variable. Within adipose for
instance, MSC bioactivity is contingent on the specific
depots from which the adipose was sourced [10,11].
Therefore, MSC bioactivity may be regarded as a func-
tional indicator discriminating differently sourced adi-
poses. Additional studies have also identified depot
specific functional features of differently sourced adi-
poses, such as regional differences in micro-RNA
expression and androgen concentration between human
omental and subcutaneous adiposes [29,30]. Finally, dis-
parity in the functional properties of white and brown
adipose tissue is well described [31]. These observations
led us to further evaluate organ specific functional dif-
ferences between differently sourced adiposes. For the
current study, we focused on organ specific features
associated with kidney sourced adipose, beginning with
analysis of the kidney associated regenerative growth
factor EPO.
The regulated expression of EPO is a key mechanistic
pathway for the control of erythropoiesis. EPO, a 34
Figure 12 Semi-quantitative RT-PCR analysis of WT1 splice
variants (KTS+/KTS-) in human kidney and non-kidney sourced
adipose stromal cells. All lanes were normalized by total mass of
cDNA: molecular weight ladder used for sizing (1), lipoaspirate
stromal cells (Lane 2), subcutaneous adipose stromal cells (Lane 3),
major calyx adipose stromal cells (Lane 4), renal pedicle stromal cells
(Lane 5). Expression of WT1 is only detectable from renal adipose.
Note that the ratio of KTS+/KTS- splice variants differs between
major calyx and renal pedicle derived cell sources derived from the
same donor.
Figure 13 FACs analysis of the distribution of WT1+ cells in
renal pedicle associated adipose stromal cells. 45.6% of renal
pedicle adipose stromal cell population was WT1+.
Figure 14 FACs analysis of the distribution of WT1+ cells in
major calyx associated adipose stromal cells. 52.4% of major
calyx adipose stromal cell population was WT1+.
Figure 15 Immuno-fluorescence analysis of the distribution of
WT1+ cells in major calyx adipose stromal cells and renal
pedicle adipose stromal cells. Note that localization of WT1
expression is cytoplasmic and nuclear. WT1 (green), DNA (red).
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kDa glycoprotein principally expressed from fetal liver
and adult kidney, is up-regulated through the O2-depen-
dant modulation of HIF-1a/2a activity. Binding of these
transcription factors to the appropriate regulatory
regions of the EPO genomic locus triggers concomitant
synthesis of EPO mRNA [14,15]. To date, expression of
EPO has been detected in the kidney, liver, brain,
spleen, lung and testis [32]. Within the kidney, the peri-
tubular interstitial fibroblasts of the cortex and medulla
have been implicated as the site of EPO production
[33,34], and an EPO expressing primary renal cell popu-
lation has recently been described [35]. Secretion of
EPO from the kidney is required for regulation of ery-
thropoeisis and to avoid severe anemia secondary to
CKD [36]. Attempts to directly address CKD-associated
anemia through treatment with recombinant EPO have
generated mixed results [37,38], leading to efforts to
develop gene and cell therapy based approaches for the
targeted delivery of EPO in a physiologically relevant
manner [35,39,40]. From a broader perspective, the
secretion of critical trophic factors such as EPO and
VEGF may be the principal mechanism responsible for
observed therapeutic efficacy of MSC in chronic and
acute injury models [28]. The angiogenic activity of
VEGF may additionally serve an anti-fibrotic function,
acting to further retard deterioration of the renal envir-
onment [41]. EPO may additionally function to enhance
cell survival [42,43].
In the current report, we show that kidney sourced
adipose represents a hitherto unidentified reservoir of
EPO producing cells. As with other previously docu-
mented sources of EPO [14,15,32,33], expression of EPO
mRNA from kidney sourced adipose stromal cells is
regulated by environmental oxygen. Observed down-reg-
ulation of EPO mRNA expression during the hypoxia-
normoxia transition is not as tightly regulated as that
shown by VEGF mRNA (Figures 5, 6, 7, 8), despite both
VEGF and EPO mRNAs being responsive to hypoxia
through the same HIF-1a/2a mediated regulatory path-
ways [15]. This apparently less stringent regulatory con-
trol of EPO mRNA is likely due to the significantly
lower relative expression levels of EPO mRNA com-
pared to VEGF mRNA [44]. That expression of EPO is
not an artifact generated from cell culture is demon-
strated by the observation that kidney sourced adipose
tissue is a reservoir for EPO expression (Figure 11).
Interestingly, Figure 11 also shows that although EPO
expression from non-kidney sourced adipose is signifi-
cantly lower relative to kidney sourced adipose, EPO is
nevertheless a specific marker within visceral sourced
adipose discriminating white from brown adipocytes. As
shown in Figure 9, expression of EPO from KiSAS cells
is equivalent to that observed from primary renal cell
populations currently under development for cell
therapy of anemias secondary to CKD [35], suggesting
that kidney sourced adipose may represent an alternate
cell source for cellular vectors for EPO delivery.
Variation in the iso-electric isotype signature of EPO
within urine and corresponding serum has been pre-
viously documented [45]. Iso-electric isotype profiling
has been used to discriminate recombinant from native
EPO in urine of athletes suspected of illicit self-medica-
tion [19]. Similarly, IEF gel electrophoresis analysis of
stromal cell populations sourced from kidney and non-
kidney depots shows that such cell types may be func-
tionally distinguished by unique differences in the pat-
tern of post-translational modification of EPO (Figure
9). Furthermore, additional iso-electric point isotypes of
EPO are observable within differently sourced adiposes
originating from the same organ, as demonstrated by
the distinctive IEF signatures of EPO expressed by
major calyx or renal pedicle-sourced adipose stromal
cells (Figure 10). This data lends credence to the notion
that major calyx and renal pedicle represent distinct adi-
pose depots within kidney.
Our observations on the differential post-translational
modification patterns of EPO expressed by kidney and
non-kidney sourced adipose stromal cells led us to
investigate the expression status of additional key renal
markers that could potentially serve to further distin-
guish between renal and non-renal adipose depots. To
this end, WT1 is a zinc finger transcription factor
broadly involved in organogenesis. WT1 acts to modu-
late the earliest stages of nephrogenesis, and may serve
as a marker for regeneration [21-23]. Expression of
WT1 mRNA is specific to kidney sourced adipose stro-
mal cells (Figure 12). WT1 mRNA is not detected from
viscerally sourced adipose. Transcriptional regulation of
WT1 is complex and multiple splice variants with dis-
tinctive biological functions have been characterized.
The KTS+ and KTS- variants of WT1 differ in the pre-
sence or absence of 3 amino acids (KTS) between zinc
fingers 3 and 4. The ratio of KTS+/KTS- WT1 splice
variants is reported to be constant across multiple tis-
sues and the manipulation of this balance can trigger
severe developmental anomalies [24]. The observation
that kidney sourced adipose stromal cells (but not non-
kidney sourced adipose stromal cells) specifically express
WT1 is consistent with observed differences in expres-
sion levels and in post-translational modification of EPO
between kidney and non-kidney sourced adipose stromal
cells (Figure 9). Observed differences in the ratio of KTS
+/KTS- WT1 splice variants within differently sourced
adipose stromal cells derived from the same organ of
the same individual is remarkable; such disparity is con-
trary to previous reports [24], but is consistent with
organ and niche specific variability in EPO IEF signa-
tures documented herein, providing further
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confirmation of depot specific functionalities within adi-
pose. Interestingly, only approximately 50% of the stro-
mal cell population derived from either major calyx or
renal pedicle depots is WT1+ (Figure 13, 14, 15), sug-
gesting that two functionally distinct cellular sub-popu-
lations may be present within these adiposes. We are
currently separating these WT1+ and WT1- sub-popula-
tions to further determine the biological significance of
this observation.
Conclusions
In conclusion, we show in this report that adipose tissue
is a novel source of EPO. We demonstrate that expres-
sion of EPO and VEGF mRNAs from adipose (kidney
and non-kidney sources) is regulated by environmental
oxygen and is directly comparable to that observed from
primary renal cells or other established sources of EPO.
Renal and non-renal sources of adipose have unique
functional properties manifested through differences in
the level of expression and post-translational modifica-
tion of EPO. These data suggest that renal and non-
renal adipose represent fundamentally distinct adipose
depots. To this end, EPO protein expressed by kidney
and non-kidney sourced adipose stromal cells is distin-
guishable based on distinctive migration patterns
through IEF gels, a consequence of differences in the
post-translational modification of EPO between the two
cell types. Furthermore, KiSAS cells recapitulate several
additional aspects of the functional phenotype of pri-
mary renal cells including expression of the key nephro-
genic transcription factor WT1, leading us to speculate
that renal adipose may be amenable towards acquisition
of tubular functionality. In this regard, we have observed
induction of established tubular markers within primary
cultures of KiSAS cells in response to modulation with
known morphogenic agents such as retinoic acid (our
unpublished observations). Renal adipose may represent
a potentially ideal alternate cell source for treatment of
chronic anemia secondary to CKD, since renal adipose
can be isolated in much larger quantities than renal pri-
mary cells and, as is the case for adipose associated with
tubular organs such as bladder, may be unaffected by
the occurrence of metastasis in renal cancer patients
[46,47].
Methods
Isolation of renal and non-renal adipose-derived cells
Human non-renal adipose was obtained either subcuta-
neously or through visceral liposuction (Zen-Bio, http://
www.zen-bio.com). Renal adipose from the renal pedicle
was dissected away from human kidney (normal adult)
donated through National Disease Research Institute
(NDRI) in compliance with all NIH guidelines governing
the use of human tissues for research purposes. Renal
adipose from the major calyx was obtained by bisection
of whole human kidney and dissection of calyx fat away
from the medulla. Canine kidneys for isolation of canine
renal adipose were obtained from the University of
North Carolina at Chapel Hill (gift of Dr. Timothy
Nichols). Rat kidneys for isolation of rat visceral and
organ associated adiposes were sourced from male
Lewis rats obtained from Charles River Labs. Regardless
of species or tissue origin, all adipose samples were pro-
cessed as follows: Adipose was extensively washed with
PBS/0.1% gentamicin (Invitrogen-Gibco) and digested
for up to 1 hour with 0.3% collagenase I (Worthington),
1% BSA in DMEM-HG (Invitrogen-Gibco) at 37°C.
Samples were centrifuged at 600 g for 20 minutes and
the adipocytic supernatant aspirated away. The remain-
ing stromal vascular fraction was re-suspended in a-
MEM/10% FBS (Invitrogen-Gibco) and placed in a tis-
sue culture incubator for 24-48 hours. Non-adherent
cell populations were removed by washing 3× with PBS.
For experiments involving hypoxic inductions, cells were
maintained in an O2-enriched (2%) incubator for the
time periods indicated. VEGF mRNA expression was
used as a control to confirm integrity of hypoxic regula-
tion pathways.
Non-Adipose Cells
Renal primary kidney cells from rat or human kidneys
were isolated as previously described (12). Human per-
ipheral blood derived mononuclear cells were isolated as
described (13). CD34+ GCSF mobilized/non-mobilized
peripheral blood mononuclear cell cDNA was purchased
from AllCells LLC. Fetal and adult hepatocyte cDNA
and keratinocyte cDNA were purchased from ScienCell
Research Laboratories.
TaqMan qRT-PCR
RNA was purified from cell samples using the RNeasy
Plus Mini Kit (Qiagen) according to the manufacturer’s
instructions. cDNA was generated from the entire final
volume of RNA using the SuperScript VILO cDNA
Synthesis Kit (Invitrogen-Gibco) according to the man-
ufacturers’ instructions. Following cDNA synthesis,
each sample was diluted 1:10 and used directly to set
up qRT-PCR as follows: 10 μl master mix (2×), 1 μl
primer/probe, 9 μl cDNA. The following TaqMan pri-
mer/probe sets were procured from Applied Biosys-
tems: rat EPO: Rn01481376_m1, Rat VEGF-A:
Rn00582935, human EPO: Hs00171267_m1, human
VEGF-A: Hs00900058_ml, human WT-1:
Hs01103754_m1. All TaqMan reactions were carried
out in an ABI 7300 real time thermal cycler using
default cycling parameters. Analysis of PCR data was
performed using the method of Relative Quantitation
(RQ) by comparative Ct.
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Iso-electric focusing gel analysis of EPO
Up to 1 × 106 cells or up to 30 mg total adipose tissue
was lysed in protein lysis buffer (50 mM Tris pH 8.0;
150 mM NaCl; 0.5% NP40 and protease inhibitors,
Roche). 10 μg of protein lysate was loaded onto a pH 3-
7 iso-electric focusing (IEF) gel (Invitrogen-Gibco) and
run out as recommended by the manufacturer. IEF gels
were transferred to nitrocellulose using the iBlot transfer
system (Invitrogen-Gibco) and probed overnight with
MAB 2871 anti-hEPO monoclonal antibody (R&D Sys-
tems) at 1/500 in TBST (Tris-buffered saline, pH 7.0,
0.1% Tween-20)/2% milk. Secondary antibody was horse
anti-mouse IgG/HRP conjugate (Vector Labs) at 1/
60000 in TBST/2% milk.
FACs and immuno-fluorescence
Cells (0.5 × 106- 1 × 106) were fixed in 2% para-formalde-
hyde and Fc receptors blocked to prevent non-specific
binding. Cells were permeabilized by incubation in PBS/
0.2% Triton X-100/10% horse serum for 30 minutes.
Cells were then incubated with a directly conjugated anti-
body against human WT1 (Santa Cruz) as recommended
by the manufacturer. Subsequent to final washing (PBS,
0.2% Triton X-100), antigen detection was performed uti-
lizing the Guava EasyCyte Mini Express Assay system
using the appropriate fluorescent channel. A minimum
of 5, 000-10, 000 events were acquired from each sample.
For immuno-fluorescence analysis, the labeled cell sus-
pension was centrifuged directly onto a poly-L-lysine
coated slide (Electron Microscopy Sciences) using a cyto-
centrifugation system (Viescor) at 1, 500 rpm for 5 min-
utes. Cells were counterstained with DAPI containing
mounting medium (Vector Labs) and viewed with a Leica
DMI 4000 B fluorescence microscope.
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